Celiac disease in first-degree relatives of patients

Margarida M. Castro-Antunes,1 Roberta Magalhães,2 Josemar M. M. Nobre,3 Bruna P. Duarte,4 Giselia A. P. Silva5

Abstract

Objective: To determine the prevalence of celiac disease and to describe the histological alterations, clinical manifestations, and conditions associated with a group of first-degree relatives of celiac disease patients in the municipality of Recife, Northeast Brazil.

Method: The study was conducted in outpatient clinics of pediatric gastroenterology located in Recife. We included in the study 174 first-degree relatives who were screened for the anti-transglutaminase IgA antibody. Those relatives who had positive serological tests were invited to undergo a small intestine biopsy (classified according to Marsh). They were also evaluated regarding weight, height, clinical symptoms and conditions associated with celiac disease. The chi-square test and Fisher’s exact test were used to assess the differences with a significance level of p < 0.05.

Results: The anti-transglutaminase IgA antibody was positive for 20.1% (34/174) of the relatives (95%CI 14.6-26.5). There was no difference in terms of positive serological tests regarding either degree of kinship or sex. Twenty-two patients underwent biopsy. Thirteen had histological alterations classified as Marsh stage 3; seven had stage 1; and two had stage zero, with a probable prevalence of 11.5%. All patients, except for one, had symptoms; the only patient with no symptoms was short.

Conclusion: Celiac disease prevalence in this group of relatives was high. All new cases identified were symptomatic or had associated conditions. In this group, there was a high frequency of individuals with positive serological tests, symptoms suggestive of celiac disease, and no evidence of villous atrophy in the intestinal mucosa.


Introduction

Celiac disease (CD) is characterized by inflammatory and autoimmune changes triggered by the ingestion of gluten in genetically susceptible individuals.1 It affects from 0.5 to 1% of the world’s population, with treatment consisting of a gluten-free diet for life. In Brazil, CD is considered a relatively rare condition. However, recent serologic studies have revealed that it is present in 0.15 to 1.75% of the general population.2-5 This frequency is similar to that found in most European countries.6

First-degree relatives of CD patients share genetic and environmental risk factors for CD. Therefore, they are at the most risk of developing the disease.7 The frequency

1. Pós-Graduação, Saúde da Criança e do Adolescente, Centro de Saúde, Universidade Federal de Pernambuco (UFPE), Recife, PE, Brazil. Ambulatório de Gastroenterologia Infantil, Instituto de Medicina Integral Professor Fernando Figueira (IMIP), Recife, PE, Brazil.
2. Laboratório Marcelo Magalhães, Recife, PE, Brazil.
3. Laboratório de Imunologia, IMIP, Recife, PE, Brazil.
4. Acadêmica, Curso Médico, UFPE, Recife, PE, Brazil. Programa Institucional de Bolsas de Iniciação Científica (PIBIC), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
5. Pós-Graduação, Saúde da Criança e do Adolescente, Centro de Saúde, UFPE, Recife, PE, Brazil. Departamento Materno Infantil, Centro de Ciências da Saúde, UFPE, Recife, PE, Brazil.


No conflicts of interest declared concerning the publication of this article.


Manuscript received Mar 9 2010, accepted for publication May 5 2010.
doi:10.2223/JPED.2013
of CD in these individuals is 10 to 20 times higher than in the general population. Because of that, there is consensus regarding the need for serologic screening in this population, even in individuals who claim to be asymptomatic.8,9

According to the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 1990 criteria, the diagnosis of CD is based on the presence of small intestinal biopsy with villous atrophy (Marsh stage 3) and presence of clinical symptoms and serological parameters of CD during gluten ingestion with relief of all symptoms with a gluten-free diet.10 However, these parameters often lead to diagnostic uncertainty. In 2005, the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) revised the ESPGHAN criteria, and issued recommendations that also addressed diagnosis in special situations.8 These guidelines recommend serological testing in individuals at risk, even if asymptomatic, after 3 years of age.

A small intestine biopsy with villous atrophy is not always observed in relatives at risk with a positive serological test for CD. In addition, many of them have unspecific symptoms or are asymptomatic.11 Currently, albeit minimal alterations in inflammatory profile (Marsh stage 1) are still not sufficient for diagnosing CD, some authors suggest that in the presence of positive serology and symptoms patients with evidence of alterations should be submitted to testing with a gluten-free diet and follow-up.12,13

Another aspect to be considered is that enteric infection and chronic malnutrition, which are highly frequent in Brazil and in other developing countries, can cause alterations in intestinal mucosa that are similar to those associated with celiac enteropathy.14,15 In addition, the racial mix in Brazil is very different from that of Europe, where most studies on CD were carried out. Therefore, CD may be specific clinical and histological characteristics in the Brazilian population.

Based on these assumptions, the objective of this study was to determine the prevalence of CD and to describe histological alterations, clinical symptoms and associated conditions in a group of first-degree relatives of CD patients in the municipality of Recife, Northeast Brazil.

Method

**Population, setting, and study design**

The present study was conducted in outpatient clinics of pediatric gastroenterology in the municipality of Recife, state of Pernambuco, Northeast Brazil, from August 2007 to March 2009. Patients with previous diagnosis of CD were identified as index cases and their first-degree relatives, older than 18 months, were invited to participate in the study. We classified as an index case the individual whose diagnosis had been established according to the ESPGHAN 1990 criteria,10 regardless of follow-up duration. Those relatives who agreed to participate in the study underwent collection of 5 mL of blood, had their weight and height measured, and completed a questionnaire about symptoms. The relatives who had positive serological tests were invited to undergo intestinal biopsy.

**Serological testing**

Three mL of blood were placed in a dry tube for serological testing. Blood samples were centrifuged, and the serum obtained through this process was stored in Eppendorf tubes at -18 °C. The serological screening for anti-tissue transglutaminase (tTG) antibodies was performed by semi-quantitative ELISA using a kit available in the market (ImmuLisa™, IMMCO Diagnostics Inc, Buffalo, NY, USA). The test was performed in duplicate in two separate readers and the individuals whose two readings were higher than 25 IU/mL were considered positive, as defined by the manufacturer.

**Intestinal biopsy**

Four to six mucosa samples were collected from the duodenal bulb and distal duodenum through digestive endoscopy. The histopathological evaluation, performed after hematoxylin and eosin staining, used Marsh’s classification for the diagnosis of CD.16

**Clinical assessment**

Weight and height were measured by the same investigator and categorized into percentiles according to the curve of the Centers for Disease Control and Prevention (CDC).17 Body mass index (BMI) was calculated using the ratio of weight by the square of height. To investigate symptoms and associated conditions, we used a questionnaire of closed answers. Signs and symptoms were grouped into three categories: 1) weight loss, 2) gastrointestinal symptoms – abdominal pain, diarrhea, constipation, abdominal distension, flatulence, fullness, and 3) non-gastrointestinal symptoms – oral ulcers, joint pain, fatigue, irritability, insomnia, alopecia, dermatitis. The morbid conditions assessed were: anemia, osteoporosis, dermatitis herpetiformis, thyroid, seizures, depression, rheumatic diseases, genetic syndromes, and chronic nephropathy.

**Statistical analysis**

The frequencies are described as percentage with their respective 95% confidence intervals (95%CI) and ages as median and percentile (P25-75%). We used chi-square test and Fisher’s exact test to analyze differences between frequencies and Student’s t test to analyze differences between means. We considered the p value < 0.05 as statistically significant.
**Ethical aspects**

A written consent form was obtained from all participants. The study was approved by the Research Ethics Committee of the Instituto de Medicina Integral Fernando Figueira (IMIP), Recife, state of Pernambuco, Brazil, and complied with the decisions of the Helsinki Declaration. Individuals who were diagnosed with CD or had positive serological tests were referred to follow-up in a specialized outpatient clinic.

**Results**

We identified 199 relatives of 66 index cases of CD, and 174 (87.4%) agreed to participate in the study and were included. All families had only one individual with a prior diagnosis of CD. There were 78 men (44.8%) and 96 women (55.2%) among the relatives. Regarding the type of kinship with the index case, 49 were fathers, 63 mothers, and 62 brothers or sisters. Parents’ age ranged between 23 and 56 years, median of 38 years (P25-75% 33-42 years), and siblings’ age ranged from 20 months to 27 years, median of 13 years (P25-75% 8-17 years). There was a predominance of females in the study population (p = 0.05).

**Serological testing**

tTG was positive in 35/174 relatives, resulting in a seroprevalence of 20.1% (95%CI: 14-26). The results of the serological tests, according to type of kinship and sex, are described in Table 1. No difference was found in the frequencies of tTG seropositivity either in terms of type of kinship with the index case or gender.

**Histology of the small intestine**

Of the relatives with positive serological tests, 22/35 (62.8%) agreed to undergo endoscopy combined with biopsy. Among them, 20/22 (90.9%) had altered biopsies: seven were compatible with Marsh stage 1 and 13 were compatible with Marsh stage 3. Considering that those patients showing altered biopsy and symptoms had CD, we found a probable CD prevalence of 11.5% (95%CI: 7.3-17.4). Figure 1 shows the sequence and distribution of the results of serological testing and biopsies.

**Symptoms**

One of two relatives with normal biopsy and positive tTG was asymptomatic, and the other one had abdominal distension and pain, diarrhea, fullness, flatulence, constipation, joint pain, fatigue, irritability, alopecia, and rheumatologic disease without a defined diagnosis. Table 2 describes age, kinship, tTG results, classification of height, BMI, histological alterations, symptoms, and associated conditions in the 20 relatives who had an altered biopsy.

**Discussion**

In our study, we found a seroprevalence of 20.1% and an estimated prevalence of CD of 11.5% in relatives of CD patients. This frequency is high and similar to those of Europe and North America. The two Brazilian studies involving relatives of CD patients that we are aware of so far were conducted in the Central South region of Brazil and found a maximum prevalence of 4.8%. Both used anti-endomysial antibody (EmA) for initial screening. We believe that the difference in seroprevalence between these studies and the present study was significant because, although the EmA testing is more specific, it is less sensitive than tTG. We decided to use tTG-IgA as the only test for screening the relatives because of its high sensitivity, low cost, and easy technique. The main cause of false-negative tTG-IgA tests is false-positive results due to cross-reactivity with other antigens.

### Table 1 - Frequency of anti-tissue transglutaminase antibodies by sex and degree of kinship with the index case

<table>
<thead>
<tr>
<th>Kinship</th>
<th>tTG present (n = 35)</th>
<th>tTG absent (n = 139), n (%)</th>
<th>Total (n = 174), n</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>95%CI</td>
<td>(n = 139), n (%)</td>
<td></td>
</tr>
<tr>
<td>Father</td>
<td>12 (24.5)</td>
<td>14.0-37.9</td>
<td>37 (75.5)</td>
<td>49</td>
</tr>
<tr>
<td>Mother</td>
<td>14 (22.2)</td>
<td>13.2-33.7</td>
<td>49 (77.8)</td>
<td>63</td>
</tr>
<tr>
<td>Sibling</td>
<td>9 (14.5)</td>
<td>7.3-25.0</td>
<td>53 (85.5)</td>
<td>62</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>14 (17.9)</td>
<td>10.6-27.6</td>
<td>64 (82.1)</td>
<td>78</td>
</tr>
<tr>
<td>Female</td>
<td>21 (21.9)</td>
<td>14.4-31.0</td>
<td>75 (78.1)</td>
<td>96</td>
</tr>
<tr>
<td>Total</td>
<td>35 (20.1)</td>
<td>14.6-26.5</td>
<td>139 (79.9)</td>
<td>174</td>
</tr>
</tbody>
</table>

95%CI = 95% confidence interval; IgA = immunoglobulin A; tTG = human IgA anti-tissue transglutaminase antibody.
Celiac disease in first-degree relatives of patients - Castro-Antunes MM et al.

IgA deficiency. In Brazil, IgA deficiency affects about 0.1% of the population, being one of the lowest rates reported in the world,\textsuperscript{22} and even considering the higher frequency among CD patients, this possibility is low in this group.

A major operational limitation of the study was the relatives’ difficulty to attend the follow-up visits because they lived in remote areas of the municipality of Recife.

Therefore, 13/34 (37%) of the seropositive patients did not undergo biopsy. It is likely that some of these patients have CD and that the prevalence of this group is higher than that we found.

Another finding of our study was that, among the 22 patients who underwent biopsy, seven had minimal alterations (Marsh stage 1). In such cases, we may raise

### Table 2 - Age, kinship with the index case, result of anti-transglutaminase antibody, percentiles of height and body mass index, histological classification, and clinical characteristics of 20 first-degree relatives with altered biopsy

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Kinship</th>
<th>tTG</th>
<th>pHgt</th>
<th>pBMI</th>
<th>Marsh</th>
<th>Symptoms and morbid conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>29</td>
<td>Father</td>
<td>32</td>
<td>2</td>
<td>96</td>
<td>1</td>
<td>Asymptomatic</td>
</tr>
<tr>
<td>2</td>
<td>36</td>
<td>Mother</td>
<td>30</td>
<td>39</td>
<td>58</td>
<td>1</td>
<td>Alopecia, autoimmune thyroiditis</td>
</tr>
<tr>
<td>3</td>
<td>33</td>
<td>Father</td>
<td>199</td>
<td>21</td>
<td>81</td>
<td>1</td>
<td>Joint pain, fatigue</td>
</tr>
<tr>
<td>4</td>
<td>11</td>
<td>Sister</td>
<td>32</td>
<td>32</td>
<td>16</td>
<td>1</td>
<td>Constipation, recurrent oral ulcers</td>
</tr>
<tr>
<td>5</td>
<td>46</td>
<td>Mother</td>
<td>28</td>
<td>8</td>
<td>67</td>
<td>1</td>
<td>Diarrhea, recurrent oral ulcers, joint pain</td>
</tr>
<tr>
<td>6</td>
<td>35</td>
<td>Mother</td>
<td>25</td>
<td>36</td>
<td>84</td>
<td>1</td>
<td>Abdominal pain and distension, diarrhea, fullness, flatulence, joint pain, fatigue, irritability, insomnia, anemia</td>
</tr>
<tr>
<td>7</td>
<td>29</td>
<td>Mother</td>
<td>29</td>
<td>1</td>
<td>80</td>
<td>1</td>
<td>Nausea, abdominal pain and distension, flatulence, constipation, recurrent oral ulcers, fatigue, insomnia, anemia</td>
</tr>
<tr>
<td>8</td>
<td>2</td>
<td>Brother</td>
<td>69</td>
<td>33</td>
<td>8</td>
<td>3</td>
<td>Weight loss, diarrhea, abdominal distension and pain, vomiting, recurrent oral ulcers</td>
</tr>
<tr>
<td>9</td>
<td>14</td>
<td>Sister</td>
<td>207</td>
<td>73</td>
<td>56</td>
<td>3</td>
<td>Constipation, fatigue, irritability</td>
</tr>
<tr>
<td>10</td>
<td>33</td>
<td>Mother</td>
<td>27</td>
<td>18</td>
<td>89</td>
<td>3</td>
<td>Abdominal pain and distension, fullness, constipation, recurrent oral ulcers, fatigue, joint pain</td>
</tr>
<tr>
<td>11</td>
<td>44</td>
<td>Mother</td>
<td>68</td>
<td>14</td>
<td>94</td>
<td>3</td>
<td>Abdominal pain and distension, vomiting, nausea, fullness, constipation, recurrent oral ulcers, thyroiditis</td>
</tr>
<tr>
<td>12</td>
<td>42</td>
<td>Father</td>
<td>175</td>
<td>9</td>
<td>51</td>
<td>3</td>
<td>Abdominal pain, fullness, flatulence, constipation, fatigue</td>
</tr>
<tr>
<td>13</td>
<td>17</td>
<td>Sister</td>
<td>30</td>
<td>0</td>
<td>18</td>
<td>3</td>
<td>Weight loss, joint pain, fatigue, anemia, rheumatic disease, osteoporosis</td>
</tr>
<tr>
<td>14</td>
<td>47</td>
<td>Father</td>
<td>45</td>
<td>18</td>
<td>64</td>
<td>3</td>
<td>Flatulence, irritability</td>
</tr>
<tr>
<td>15</td>
<td>45</td>
<td>Mother</td>
<td>81</td>
<td>3</td>
<td>79</td>
<td>3</td>
<td>Abdominal pain, fullness, abdominal distension, constipation, joint pain, fatigue, alopecia, anemia</td>
</tr>
<tr>
<td>16</td>
<td>28</td>
<td>Mother</td>
<td>113</td>
<td>20</td>
<td>52</td>
<td>3</td>
<td>Weight loss, nausea, constipation, joint pain, fatigue, irritability, depression</td>
</tr>
<tr>
<td>17</td>
<td>14</td>
<td>Sister</td>
<td>26</td>
<td>53</td>
<td>25</td>
<td>3</td>
<td>Weight loss, nausea, fullness, abdominal distension, flatulence, constipation, recurrent oral ulcers, fatigue, irritability</td>
</tr>
<tr>
<td>18</td>
<td>11</td>
<td>Sister</td>
<td>33</td>
<td>49</td>
<td>48</td>
<td>3</td>
<td>Constipation, recurrent oral ulcers, alopecia</td>
</tr>
<tr>
<td>19</td>
<td>36</td>
<td>Father</td>
<td>55</td>
<td>73</td>
<td>76</td>
<td>3</td>
<td>Abdominal pain and distension, diarrhea, fullness, flatulence, recurrent oral ulcers, joint pain, insomnia</td>
</tr>
<tr>
<td>20</td>
<td>46</td>
<td>Mother</td>
<td>25</td>
<td>2</td>
<td>72</td>
<td>3</td>
<td>Abdominal pain and distension, joint pain, fatigue</td>
</tr>
</tbody>
</table>

pHgt = height classification in percentiles according to the 2000 CDC; pBMI = classification of body mass index in percentiles according to the 2000 CDC; tTG = human anti-tissue transglutaminase antibody. Biopsy alterations classified according to Marsh.
IgA = immunoglobulin A; tTG = human anti-tissue transglutaminase antibody.

Figure 1 - Flowchart of the research with distribution of the results of the serological tests and biopsies, classified according to Marsh.

These data reinforce the need for active search using serological testing in relatives of CD patients, even in the non-European populations. In developing countries, serological testing and follow-up are essential to establish the diagnosis in relatives. We also suggest that, in cases with inconclusive biopsy that have some symptoms, tests with gluten-free diet and new biopsies for evaluation should be considered.

Acknowledgements

The authors would like to thank Sérgio Santos for collecting, transporting and processing the blood samples.

We are also grateful to the Laboratory of Immunopathology Keizo Asami (LIKA), Universidade Federal de Pernambuco (UFPE) for the centrifugation and storage of the blood samples.

References


the following possibilities: a false-positive serological test, the sample collected was not obtained in an affected area of the small intestine, or CD was at an early stage and there was not villous atrophy. In this population, it is important to consider the differential diagnosis of environmental enteropathy, which is endemic in these regions, and may have clinical and histological symptoms similar to CD. Similar data were found in India, Egypt, and Turkey, countries where the population lives in conditions comparable to those of Brazil. In this context, serological testing and follow-up of clinical response to the gluten-free diet are essential for diagnosis.

All patients diagnosed in the present study, except for one, were symptomatic, and the patient who reported to be asymptomatic was short. Possibly because their symptoms were less intense and less specific, those patients were not motivated to seek a diagnosis. Although many studies have already demonstrated that a high proportion of patients with constipation, dyspepsia, and irritable bowel syndrome have undiagnosed CD, the diagnostic suspicion in such cases remains low.


Correspondence: Margarida M Castro-Antunes
Av. Beira Rio, 240/2402, Ilha do Retiro
CEP 50750-400 - Recife, PE - Brazil
Tel.: +55 (81) 3446.8660
E-mail: margarida.mmcastro@gmail.com
This article has received corrections asked by the editor on 2011 in agreement with the ERRATUM published in Volume 87 Number 1. (http://www.scielo.br/pdf/jped/v87n1/en_v87n01a15.pdf)